Ibuprofen/famotidine

Drug Profile

Ibuprofen/famotidine

Alternative Names: Duexa; Duexis; Famotidine/ibuprofen; HZT-501

Latest Information Update: 27 Mar 2015

Price : $50

At a glance

  • Originator Horizon Therapeutics
  • Developer Horizon Pharma; Horizon Pharma USA
  • Class Antiulcers; Gastric antisecretories; Nonsteroidal anti-inflammatories; Phenylpropionates; Thiazoles
  • Mechanism of Action Cyclooxygenase inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Musculoskeletal pain; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
  • Registered Ankylosing spondylitis

Most Recent Events

  • 27 Mar 2015 Ibuprofen/famotidine is still registered for prevention of Ankylosing spondylitis, NSAID-induced ulcer, Osteoarthritis and Rheumatoid arthritis in United Kingdom, and is still in preregistration for Musculoskeletal pain and NSAID-induced ulcer in European Union
  • 12 Mar 2013 Ibuprofen/famotidine is available for licensing in Europe as of 07 Mar 2013. http://www.horizonpharma.com/
  • 07 Mar 2013 Registered for Ankylosing spondylitis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top